{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:41:36Z","timestamp":1661388096928},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Schizophrenia is a serious mental health condition characterised by distortions in thought processes, perception, mood, sense of self, and behaviour. Lurasidone, a second-generation atypical antipsychotic, represents an additional treatment option alongside existing antipsychotics for adolescents and adults with schizophrenia. An economic model was developed to evaluate the incremental costs of lurasidone as a first-line treatment option compared to existing antipsychotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Markov model was developed to estimate the cost impact of lurasidone as a first-line treatment option for both adolescents and adults. The sequence-based model incorporated the following health states: stable (no relapse or discontinuation), discontinuation (due to adverse events or other reasons), and relapse. Data used to determine the movement of patients between health states were obtained from network meta-analyses (NMAs). The time horizon ranged from three to five years (depending on the patient population) and a six-weekly cycle length was used. Unit costs and resource use were reflective of the UK NHS and Personal Social Services and consisted of the following categories: outpatient, adverse events, primary and residential care. Extensive deterministic sensitivity analysis was undertaken to assess the level of uncertainty associated with the base case results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Lurasidone is demonstrated to be cost-saving as a first-line treatment within the adolescent and adult populations when compared to second-line and third-line respectively. Lurasidone is more expensive in terms of treatment costs, resource use (in the stable health state) and the treatment of adverse events. However, these costs are outweighed by the savings associated with the relapse health state. Lurasidone remains cost-saving when inputs are varied in sensitivity analysis and scenario analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Lurasidone is a cost-saving first-line treatment for schizophrenia for both adolescents and adults.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08436-x","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:02:49Z","timestamp":1661385769000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom"],"prefix":"10.1186","volume":"22","author":[{"given":"Amy","family":"Dymond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"8436_CR1","volume-title":"Mental disorders: Schizophrenia","author":"World Health Organization (WHO)","year":"2019","unstructured":"World Health Organization (WHO). Mental disorders: Schizophrenia. 2019.Available from:https:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/."},{"key":"8436_CR2","volume-title":"Schizophrenia - Topic","author":"National Institute of Mental Health","year":"2019","unstructured":"National Institute of Mental Health. Schizophrenia - Topic. Schizophrenia - Topic. https:\/\/www.nimh.nih.gov\/health\/topics\/schizophrenia\/index.shtml."},{"key":"8436_CR3","volume-title":"Psychosis and schizophrenia in children and young people: recognition and management (CG155). London","author":"National Institute for Health and Care Excellence","year":"2013","unstructured":"National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management (CG155). London. 2013. Available from: https:\/\/www.nice.org.uk\/guidance\/cg155."},{"key":"8436_CR4","doi-asserted-by":"publisher","unstructured":"Essali N, Hanafi I, Essali A. Cariprazine versus placebo for schizophrenia.\u00a0Cochrane Database Syst Rev. 2016;(5):Art. No.: CD012207. https:\/\/doi.org\/10.1002\/14651858.CD012207. Accessed 23 Aug 2022.","DOI":"10.1002\/14651858.CD012207"},{"issue":"12","key":"8436_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","volume":"17","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206\u201327.","journal-title":"Mol Psychiatry"},{"key":"8436_CR6","unstructured":"European Medicines Agency. Latuda. Amsterdam. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/latuda.[13 Oct\u00a02020]"},{"key":"8436_CR7","unstructured":"National Institute for Health and Care Excellence. Choosing and delivering interventions for psychosis and schizophrenia in adults.. \u00a0Available from: https:\/\/pathways.nice.org.uk\/pathways\/psychosis-and-schizophrenia\/choosing-and-delivering-interventions-for-psychosis-and-schizophrenia-in-adults#content=view-node%3Anodes-choosing-antipsychotic-medication.\u00a0[cited \u00a020 July 2021]."},{"key":"8436_CR8","volume-title":"Antipsychotics","author":"Royal College of Psychiatrists","year":"2019","unstructured":"Royal College of Psychiatrists. Antipsychotics. 2019. Available from: https:\/\/www.rcpsych.ac.uk\/mental-health\/treatments-and-wellbeing\/antipsychotics."},{"issue":"1","key":"8436_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","volume":"34","author":"TR Barnes","year":"2020","unstructured":"Barnes TR, Drake R, Paton C, Cooper SJ, Deakin B, Ferrier IN, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British association for psychopharmacology. J Psychopharmacol. 2020;34(1):3\u201378.","journal-title":"J Psychopharmacol"},{"key":"8436_CR10","volume-title":"Haloperidol Oral Solution BP 10 mg\/5 ml","author":"Electronic Medicine Compendium","year":"2018","unstructured":"Electronic Medicine Compendium. Haloperidol Oral Solution BP 10 mg\/5 ml. 2018. Available from: https: \/\/www.medicines.org.uk\/emc\/product\/4521\/smpc."},{"key":"8436_CR11","volume-title":"Aripiprazole 5mg tablets","author":"Electronic Medicine Compendium","year":"2020","unstructured":"Electronic Medicine Compendium. Aripiprazole 5mg tablets. 2020. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/7073\/smpc."},{"key":"8436_CR12","volume-title":"Invega 3 mg prolonged-release tablets","author":"Electronic Medicine Compendium","year":"2018","unstructured":"Electronic Medicine Compendium. Invega 3 mg prolonged-release tablets. 2018. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6816\/smpc."},{"key":"8436_CR13","volume-title":"Psychosis and schizophrenia in adults: the NICE guideline on treatment and management.","author":"National Collaborating Centre for Mental Health","year":"2014","unstructured":"National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: the NICE guideline on treatment and management. 2014."},{"key":"8436_CR14","volume-title":"Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)","author":"National Institute for Health and Care Excellence","year":"2011","unstructured":"National Institute for Health and Care Excellence. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213). 2011. Available from: https:\/\/www.nice.org.uk\/guidance\/ta213."},{"key":"8436_CR15","volume-title":"Systematic review, feasibility assessment and network meta-analysis of treatments for adolescents with schizophrenia [CRD42021244609]","author":"D Watkins","year":"2021","unstructured":"Watkins D, Wilson K, Wood H, Beale S, Patterson J, Mclean B. Systematic review, feasibility assessment and network meta-analysis of treatments for adolescents with schizophrenia [CRD42021244609]. 2021."},{"key":"8436_CR16","volume-title":"Systematic review and feasibility assessment for a network meta-analysis of treatments for schizophrenia [CRD42020167883]","author":"A Sanderson","year":"2020","unstructured":"Sanderson A, McCool R, Wood H, Bunney M, Phalguni A. Systematic review and feasibility assessment for a network meta-analysis of treatments for schizophrenia [CRD42020167883]. 2020."},{"key":"8436_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/NDT.S282856","volume":"17","author":"B Kearns","year":"2021","unstructured":"Kearns B, Cooper K, Cantrell A, Thomas C. Schizophrenia treatment with second-generation antipsychotics: a multi-country comparison of the costs of cardiovascular and metabolic adverse events and weight gain. Neuropsychiatr Dis Treat. 2021;17:125\u201337.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10202","key":"8436_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;394(10202):939\u201351.","journal-title":"The Lancet"},{"issue":"1","key":"8436_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"M Srisurapanont","year":"2021","unstructured":"Srisurapanont M, Suttajit S, Likhitsathian S, Maneeton B, Maneeton N. A network meta-analysis of the dose\u2013response effects of lurasidone on acute schizophrenia. Sci Rep. 2021;11(1):1\u20133.","journal-title":"Sci Rep"},{"key":"8436_CR20","doi-asserted-by":"crossref","unstructured":"Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. 2013(11):CD003082.","DOI":"10.1002\/14651858.CD003082.pub3"},{"issue":"1","key":"8436_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2011.143","volume":"18","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53\u201366.","journal-title":"Mol Psychiatry"},{"key":"8436_CR22","volume-title":"Why does Clozapine cause weight gain?","author":"Health Research Authority","year":"2013","unstructured":"Health Research Authority. Why does Clozapine cause weight gain? 2013. Available from:  https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/why-does-clozapine-cause-weight-gain\/."},{"key":"8436_CR23","volume-title":"Deriving transition probabilities for decision models","author":"R Gidwani","year":"2014","unstructured":"Gidwani R. Deriving transition probabilities for decision models. 2014. Available from: https:\/\/pdfs.semanticscholar.org\/5c71\/d24a836b8a88fa83ac9f74d154163bea3e79.pdf."},{"key":"8436_CR24","volume-title":"National life tables: UK (2017 to 2019)","author":"Office of National Statistics","year":"2021","unstructured":"Office of National Statistics. National life tables: UK (2017 to 2019). 2021. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables.."},{"issue":"1","key":"8436_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67\u201376.","journal-title":"Epidemiol Rev"},{"key":"8436_CR26","unstructured":"National Institute for Health and Care Excellence. Lurasidone hydrochloride. Available from: https:\/\/bnf.nice.org.uk\/medicinal-forms\/lurasidone-hydrochloride.html."},{"key":"8436_CR27","volume-title":"Drugs and pharmaceutical electronic market information tool (eMIT)","author":"Department of Health and Social Care","year":"2021","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT). 2021. Available from: https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit.."},{"key":"8436_CR28","unstructured":"National Institute for Health and Care Excellence. Paliperidone. Available from: https:\/\/bnf.nice.org.uk\/medicinal-forms\/paliperidone.html."},{"key":"8436_CR29","unstructured":"National Institute for Health and Care Excellence. Cariprazine. Available from: https:\/\/bnf.nice.org.uk\/medicinal-forms\/cariprazine.html."},{"key":"8436_CR30","unstructured":"National Institute for Health and Care Excellence. Olanzapine. Available from: https:\/\/bnf.nice.org.uk\/drug\/olanzapine.html#indicationsAndDoses."},{"key":"8436_CR31","unstructured":"Curtis L, Burns A. Unit Costs of Health and Social Care 2020. Caterbury: 2020. Available from: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2020\/."},{"key":"8436_CR32","volume-title":"Hospital episode statistics for admitted patient care and outpatient data","author":"NHS Digital","year":"2021","unstructured":"NHS Digital. Hospital episode statistics for admitted patient care and outpatient data. 2021. Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/hospital-episode-statistics-for-admitted-patient-care-outpatient-and-accident-and-emergency-data."},{"key":"8436_CR33","volume-title":"Unit costs of health and social care","author":"L Curtis","year":"2007","unstructured":"Curtis L, Burns A. Unit costs of health and social care. 2007."},{"key":"8436_CR34","volume-title":"Clozaril 25mg and 100mg Tablets","author":"Electronic Medicine Compendium","year":"2020","unstructured":"Electronic Medicine Compendium. Clozaril 25mg and 100mg Tablets. 2020. Available from:  https:\/\/www.medicines.org.uk\/emc\/medicine\/32564.."},{"key":"8436_CR35","volume-title":"National Schedule of NHS Costs 2018\/19","author":"National Health Service","year":"2021","unstructured":"National Health Service. National Schedule of NHS Costs 2018\/19. 2021."},{"issue":"7","key":"8436_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40273-016-0405-0","volume":"34","author":"K Rajagopalan","year":"2016","unstructured":"Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-utility analysis of lurasidone versus aripiprazole in adults with schizophrenia. Pharmacoeconomics. 2016;34(7):709\u201321.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"8436_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1192\/bjpo.bp.115.002576","volume":"2","author":"YJ Zhao","year":"2016","unstructured":"Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, et al. Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016;2(1):59\u201366.","journal-title":"BJPsych Open"},{"issue":"1","key":"8436_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41537-018-0053-9","volume":"4","author":"J Spertus","year":"2018","unstructured":"Spertus J, Horvitz-Lennon M, Abing H, Normand SL. Risk of weight gain for specific antipsychotic drugs: a meta-analysis. NPJ Schizophrenia. 2018;4(1):12.","journal-title":"NPJ Schizophrenia"},{"issue":"4","key":"8436_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.mp.4002136","volume":"14","author":"S Leucht","year":"2009","unstructured":"Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429\u201347.","journal-title":"Mol Psychiatry"},{"key":"8436_CR40","unstructured":"York Health Economics Consortium (YHEC). Network Meta-Analysis (NMA). York: 2016. Available from: https:\/\/yhec.co.uk\/glossary\/network-meta-analysis-nma\/."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08436-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08436-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08436-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:03:52Z","timestamp":1661385832000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08436-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8436"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08436-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval and consent to participate was not required along with the statement for guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of York Health Economics Consortium who were commissioned by Angelini to provide consultancy, develop the economic model, and write the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1084"}}